Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will ...

Discover key insights with the "Hypoglycemia - Global Clinical Trials Review, 2025," providing a detailed overview of the global hypoglycemia clinical trials landscape. Access top-line data on trial ...

Vertex Pharmaceuticals' new therapy, zimislecel, has potential to be a "functional cure," experts say. To continue reading ...

Academic detailing plus pre-visit patient activation was associated with sustained diabetes deprescribing rates at 12 months in older adults with T2D.

For individuals with Type 1 diabetes, the risk of hypoglycemia, dangerously low blood sugar, is a constant concern. When ...